Glaukos Reports Positive Results From Potential Eye Disease Treatment Study

MT Newswires Live10-17

Glaukos (GKOS) on Wednesday announced positive topline results from its phase 3 confirmatory trial for Epioxa, a corneal cross-linking treatment for keratoconus, a rare corneal disorder.

The trial achieved its primary efficacy endpoint, showing a clinically significant and statistically meaningful improvement in maximum corneal curvature, or Kmax at 12 months.

Key findings reveal a Kmax treatment effect of -1.0 diopter, with 91.5% of treated patients completing the 12-month trial with no reported serious treatment-related adverse events, and no evidence of systemic effects or changes in corneal endothelial cell counts, the company said.

Results from this second phase 3 confirmatory trial, along with the first phase 3 trial, are expected to support Glaukos' planned new drug application submission by the end of 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476772339?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476772339","market":"sh","top_or_hot":-1,"title":"Glaukos Reports Positive Results From Potential Eye Disease Treatment Study","media":"MT Newswires Live","content":"<html><body><p> Glaukos (GKOS) on Wednesday announced positive topline results from its phase 3 confirmatory trial for Epioxa, a corneal cross-linking treatment for keratoconus, a rare corneal disorder.</p><p>The trial achieved its primary efficacy endpoint, showing a clinically significant and statistically meaningful improvement in maximum corneal curvature, or Kmax at 12 months.</p><p>Key findings reveal a Kmax treatment effect of -1.0 diopter, with 91.5% of treated patients completing the 12-month trial with no reported serious treatment-related adverse events, and no evidence of systemic effects or changes in corneal endothelial cell counts, the company said.</p><p>Results from this second phase 3 confirmatory trial, along with the first phase 3 trial, are expected to support Glaukos' planned new drug application submission by the end of 2024.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaukos Reports Positive Results From Potential Eye Disease Treatment Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaukos Reports Positive Results From Potential Eye Disease Treatment Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 05:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Glaukos (GKOS) on Wednesday announced positive topline results from its phase 3 confirmatory trial for Epioxa, a corneal cross-linking treatment for keratoconus, a rare corneal disorder.The trial ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476772339","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476772339","pubTimestamp":1729114579,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Glaukos  on Wednesday announced positive topline results from its phase 3 confirmatory trial for Epioxa, a corneal cross-linking treatment for keratoconus, a rare corneal disorder.The trial achieved its primary efficacy endpoint, showing a clinically significant and statistically meaningful improvement in maximum corneal curvature, or Kmax at 12 months.Key findings reveal a Kmax treatment effect of -1.0 diopter, with 91.5% of treated patients completing the 12-month trial with no reported serious treatment-related adverse events, and no evidence of systemic effects or changes in corneal endothelial cell counts, the company said.Results from this second phase 3 confirmatory trial, along with the first phase 3 trial, are expected to support Glaukos' planned new drug application submission by the end of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","GKOS":"Glaukos Corp","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4548":"巴美列捷福持仓"},"translate_title":"Glaukos报告潜在眼病治疗研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Glaukos (GKOS) on Wednesday announced positive topline results from its phase 3 confirmatory trial for Epioxa, a corneal cross-linking treatment for keratoconus, a rare corneal disorder.The trial achieved its primary efficacy endpoint, showing a clinically significant and statistically meaningful improvement in maximum corneal curvature, or Kmax at 12 months.Key findings reveal a Kmax treatment effect of -1.0 diopter, with 91.5% of treated patients completing the 12-month trial with no reported serious treatment-related adverse events, and no evidence of systemic effects or changes in corneal endothelial cell counts, the company said.Results from this second phase 3 confirmatory trial, along with the first phase 3 trial, are expected to support Glaukos' planned new drug application submission by the end of 2024.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476772339"}